Literature DB >> 24173318

Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase-9.

Mei Ling Jin1, Sun Young Park, Young Hun Kim, Geuntae Park, Sang Joon Lee.   

Abstract

Halofuginone (HF) is extracted from Dichroa febrifuga, a plant used in traditional medicine. We report that the HF extract inhibits the growth of breast cancer cells and induces the generation of reactive oxygen species (ROS) and apoptosis, an important feature of potential anticancer agents. In addition, HF significantly reduces the migration and invasion of MCF-7 and MDA-MB-231 human breast cancer cells after 12-O-tetraecanoylphorbol-13-acetate (TPA) stimulation. As matrix metalloproteinase-9 plays a critical role in tumor metastasis, we analyzed its expression with the HF extract treatment. Western blot analysis and gelatin zymography showed that HF suppresses MMP-9 expression and activity concentration-dependently. HF also decreases the nuclear protein levels of nuclear factor kappa B (NF-κB) and c-fos (AP-1), critical transcription factors regulating MMP-9 expression through binding the MMP-9 promoter region. Luciferase assays showed that HF decreases TPA-induced MMP-9 promoter binding activities of NF-κB and AP-1. Taken together, these are the first results indicating that halofuginone may represent a promising new agent for breast cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24173318     DOI: 10.3892/ijo.2013.2157

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  16 in total

Review 1.  The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis.

Authors:  Josiah Ochieng; Gladys N Nangami; Olugbemiga Ogunkua; Isabelle R Miousse; Igor Koturbash; Valerie Odero-Marah; Lisa J McCawley; Pratima Nangia-Makker; Nuzhat Ahmed; Yunus Luqmani; Zhenbang Chen; Silvana Papagerakis; Gregory T Wolf; Chenfang Dong; Binhua P Zhou; Dustin G Brown; Anna Maria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Rabeah Al-Temaimi; Fahd Al-Mulla; William H Bisson; Sakina E Eltom
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

2.  Halofuginone suppresses growth of human uterine leiomyoma cells in a mouse xenograft model.

Authors:  Faezeh Koohestani; Wenan Qiang; Amy L MacNeill; Stacy A Druschitz; Vanida A Serna; Malavika Adur; Takeshi Kurita; Romana A Nowak
Journal:  Hum Reprod       Date:  2016-04-29       Impact factor: 6.918

3.  Effect of halofuginone on the inhibition of proliferation and invasion of hepatocellular carcinoma HepG2 cell line.

Authors:  Sibo Huo; Huiqiu Yu; Chusheng Li; Jiayu Zhang; Tongjun Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

4.  Halofuginone improves caustic-induced oxidative injury of esophagus in rats.

Authors:  Kıvılcım Karadeniz Cerit; Berna Karakoyun; Elif Bahadır; Meral Yüksel; Nurdan Bülbül; Feriha Ercan; E Tolga Dağlı; Berrak Ç Yeğen
Journal:  Esophagus       Date:  2017-10-14       Impact factor: 4.230

5.  Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.

Authors:  Audrey Lamora; Mathilde Mullard; Jérôme Amiaud; Régis Brion; Dominique Heymann; Françoise Redini; Franck Verrecchia
Journal:  Oncotarget       Date:  2015-06-10

6.  High level of αB-crystallin contributes to the progression of osteosarcoma.

Authors:  Qing-Ming Shi; Jun Luo; Kai Wu; Ming Yin; Yu-Rong Gu; Xi-Gao Cheng
Journal:  Oncotarget       Date:  2016-02-23

7.  Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism.

Authors:  Guo-Qing Chen; Cheng-Fang Tang; Xiao-Ke Shi; Cheng-Yuan Lin; Sarwat Fatima; Xiao-Hua Pan; Da-Jian Yang; Ge Zhang; Ai-Ping Lu; Shu-Hai Lin; Zhao-Xiang Bian
Journal:  Oncotarget       Date:  2015-09-15

8.  Halofuginone inhibits radiotherapy-induced epithelial-mesenchymal transition in lung cancer.

Authors:  Yang Chen; Weishuai Liu; Peng Wang; Hailing Hou; Ningbo Liu; Linlin Gong; Youyou Wang; Kai Ji; Lujun Zhao; Ping Wang
Journal:  Oncotarget       Date:  2016-11-01

9.  Halofuginone ameliorates inflammation in severe acute hepatitis B virus (HBV)-infected SD rats through AMPK activation.

Authors:  Weili Zhan; Yanhong Kang; Ning Chen; Chongshan Mao; Yi Kang; Jia Shang
Journal:  Drug Des Devel Ther       Date:  2017-10-10       Impact factor: 4.162

10.  Lippia origanoides extract induces cell cycle arrest and apoptosis and suppresses NF-κB signaling in triple-negative breast cancer cells.

Authors:  Vishak Raman; Jorge Luis Fuentes Lorenzo; Elena E Stashenko; Morris Levy; Maria M Levy; Ignacio G Camarillo
Journal:  Int J Oncol       Date:  2017-10-19       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.